<DOC>
	<DOCNO>NCT00529373</DOCNO>
	<brief_summary>The purpose event-driven base study determine safety efficacy , especially fracture-risk reduction , odanacatib postmenopausal woman diagnose osteoporosis . In placebo-controlled extension base study , participant continue receive blind study medication total 5 year blind study medication combine base study extension . After participant receive least 5 year blind study medication , invite enroll second extension study receive open-label odanacatib additional 5 year .</brief_summary>
	<brief_title>A Study MK-0822 Postmenopausal Women With Osteoporosis Assess Fracture Risk ( MK-0822-018 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Postmenopausal woman ( least 5 year ) â‰¥65 year age low bone mineral density Ambulatory ( able walk ) Must take osteoporosis therapy metabolic bone disorder osteoporosis Has hip fracture Currently participate another drug study</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>